ASN Kidney Week: Research uncovers why dialysis and transplant patients are more likely to die from COVID-19


People with kidney failure who are on dialysis or who have received a kidney transplant face a higher risk of dying from COVID-19—and new research has revealed that these individuals have profound immune system-related differences compared with people with normal kidney function, with these differences being further amplified by SARS-CoV-2 infection.

This is according to the findings of a study presented at American Society of Nephrology (ASN) Kidney Week (2–7 November 2021, virtual). The study included 32 patients who were on haemodialysis, or who received a kidney transplant, and were hospitalised for COVID-19, as well as 12 dialysis or transplant patients without COVID-19 and 10 healthy controls.

Patients with a severe COVID-19 course were older and showed lower counts of immune cells called lymphocytes and monocytes compared to patients with a benign disease course. Patients without COVID-19 had lower numbers of all major immune cell subsets compared with healthy patients, and these numbers were further reduced in patients with COVID-19—especially in patients with a severe disease course.

Investigators noted several other immune system-related differences between these patients and the healthy controls.

“Although dialysis and kidney transplant patients are inherently heterogeneous groups, the immunological abnormalities during COVID-19 are similar across the two cohorts, with the exception of more pronounced defects in innate immunity and a dampened antibody response in kidney transplant patients,” said lead author Stefania Affatato (Università di Brescia, ASST Spedali Civili di Brescia, Brescia, Italy).


Please enter your comment!
Please enter your name here